Myasthenia Gravis ( MG ) Resource Utilization, Epidemiology, Survival, and Treatment Patterns ( MG ‐ REST ): Estimating the Clinical and Economic Burden in Ontario, Canada
European Journal of Neurology · 2026
DOI: 10.1111/ene.70694 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Carolina Barnett-Tapia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Myasthenia Gravis, Health Care Costs, Cost of Illness, Patient Acceptance of Health Care. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson and Johnson.
Abstract (Originalsprache)
Objective
The study purpose was to quantify the epidemiology, healthcare resource utilization (HCRU), costs, survival, and treatment patterns of myasthenia gravis (MG) in Canada using population‐based administrative data.
Methods
A retrospective cohort study was conducted using administrative data in Ontario, Canada from 2013 to 2020. MG cases were identified using a validated algorithm. Outcomes included MG incidence and prevalence, myasthenic crisis incidence and prevalence, mortality, survival, HCRU, healthcare costs, and treatment patterns (among patients receiving public drug coverage; i.e., individuals ≥ 65 years).
Results
The cohort included 2601 individuals with MG (mean age 65.7 years; 46.7% female). Standardized incidence remained stable (3.2–4.0 per 100,000), while prevalence increased from 36 to 42 per 100,000 from 2013/14 to 2019/20. Myasthenic crisis occurred in 8.9% of individuals over the study, with a post‐diagnosis incidence rate of 2.6 per 100 person‐years and 30‐day mortality of 28.1%. 5‐year overall survival was 75%, declining to 39% among those with crisis. Mean annual HCRU and direct costs were highest in the first‐year post‐diagnosis (10.0 specialists visits and CAD $31,693), decreasing in subsequent years. Mean crisis‐related costs were CAD $32,948 per person‐month in the first 90 days after crisis. During the study among patients ≥ 65 years, most (77.9%) received AChE inhibitors, and excluding AChE inhibitors, corticosteroids were the most common first‐line treatment (62.7%).
Conclusions
MG imposes a substantial clinical and economic burden particularly among patients experiencing myasthenic crisis. These findings underscore the need for early intervention and improved access to advanced therapies to mitigate long‐term morbidity and healthcare costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
- Division of Neurology, Department of Medicine, University Health Network and University of Toronto, Toronto, Canada.
- Johnson & Johnson Innovative Medicine, Toronto, Canada.
- IQVIA Solutions Inc., Toronto, Canada.
- Division of Neurology, Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Canada.
ORCID-Profile: Carolina Barnett-Tapia, Ryan Ng
Förderung
- Johnson and Johnson
Zitieren
APA
Barnett-Tapia, C., Quansah, K., Erman, A., Nath, N., Golden, S., Ng, R., Sharma, A., & Breiner, A. (2026). Myasthenia Gravis ( MG ) Resource Utilization, Epidemiology, Survival, and Treatment Patterns ( MG ‐ REST ): Estimating the Clinical and Economic Burden in Ontario, Canada. European Journal of Neurology. https://doi.org/10.1111/ene.70694
Vancouver
Barnett-Tapia C, Quansah K, Erman A, Nath N, Golden S, Ng R, et al. Myasthenia Gravis ( MG ) Resource Utilization, Epidemiology, Survival, and Treatment Patterns ( MG ‐ REST ): Estimating the Clinical and Economic Burden in Ontario, Canada. European Journal of Neurology. 2026. doi:10.1111/ene.70694
BibTeX
@article{BarnettTapia2026,
author = {Barnett-Tapia, Carolina and Quansah, Kobina and Erman, Aysegul and Nath, Nikhil and Golden, Shane and Ng, Ryan and Sharma, Arushi and Breiner, Ari},
title = {Myasthenia Gravis ( MG ) Resource Utilization, Epidemiology, Survival, and Treatment Patterns ( MG ‐ REST ): Estimating the Clinical and Economic Burden in Ontario, Canada},
journal = {European Journal of Neurology},
year = {2026},
doi = {10.1111/ene.70694}
}
EUVIMED